Freenome, Inc.
Healthcare AI
Diagnostics and early cancer detection (blood-based multiomics screening)
Public
Freenome is an AI-driven biotechnology company focused on early cancer detection through blood-based, multiomics screening tests, using machine learning and computational biology to identify cancer in its earliest, most treatable stages.
Company Details
- Website
- freenome.com
- Headquarters
- Brisbane, California, United States[10][13][15][16]
- Founded
- 2014
- Funding
- $600M+ (including $254M round announced Feb 2024)[3][8][14][17]
Subscriber Intelligence
- • Deal signal alerts for this company
- • Sentiment & risk scoring
- • Competitive framework analysis
- • Regulatory event monitoring